

FIGURE 8. **Maturation of hypertrophic chondrocyte is impaired in metatarsals treated with FGF23/sKL.** *A* and *B*, metatarsal rudiments were isolated from E 15.5 embryos and cultured in the presence or absence of FGF23 (300 ng/ml) and sKL (300 ng/ml) for 6 days. Expression levels of *Col10a1* were analyzed by *In situ* hybridization (*A*) and real-time-RT-PCR (*B*) ($n = 3$). *C*, primary chondrocytes were treated with chondrogenic media in the presence or absence of FGF23 (100 ng/ml) and sKL (100 ng/ml) for 6 days. Expression levels of *Col10a1* were determined by real-time RT-PCR ($n = 3$). *D* and *E*, metatarsals were cultured in the presence of various concentrations of FGF23 and sKL (*D*), or FGF23 (300 ng/ml), sKL (300 ng/ml), or both (*E*) for 12 days. On day 12, the calcein incorporated area was visualized and quantified ($n = 3–4$). *RZ*: resting zone, *PZ*: proliferating zone, *HZ*: hypertrophic zone. The figures shown are the representative from at least three independent experiments. The values were expressed as mean ± S.E. *, $p < 0.01$; **, $p < 0.05$. *ns*, not significant.

ple, FGF23 has been recently shown to be responsible for the development of left ventricular hypertrophy through activating calcineurin-NFAT signaling pathway in mice (26). Non-canonical activity of FGF23 could be operative as well in chondrocytes as evidenced by the previous study in which *Fgf23* and *Slc34a1* genes were deleted in mice (10). The lack of *Slc34a1* in *Fgf23*-deficient mice did not correct the decreased number of hypertrophic chondrocytes in *Fgf23*-deficient mice despite of the correction of serum phosphate levels, suggesting the presence of phosphate-independent action of FGF23 in chondrocytes; however, the precise mechanisms of phosphate-independent function of FGF23 in chondrocyte biology remain to be elucidated.

Initially, we demonstrated *in vitro* that FGF23 can mediate its signals in the presence of sKL. As previously reported, α-Klotho expression was extremely low in chondrogenic cells. In line with this, FGF23 alone could not activate ERK or induce *Egr1* expression in chondrogenic cells. Since there is an increasing amount of evidence that demonstrates the biological function of sKL in mice (12–15), we assessed the functional interaction between FGF23 and sKL in chondrogenic cells. In the current study, we utilized ~130 kDa of sKL produced by ectodomain



FIGURE 9. **Indian Hedgehog partly mediates the suppressive effect of FGF23/sKL on the longitudinal growth of metatarsals.** *A* and *B*, primary chondrocytes were treated with chondrogenic media in the presence or absence of FGF23 (100 ng/ml) and sKL (100 ng/ml) for 2 days. Metatarsal rudiments were cultured in the presence or absence of FGF23 (300 ng/ml) and sKL (300 ng/ml) for 6 days. Expression levels of *Ihh* were determined by real-time RT-PCR ($n = 4$) (*A*) and immunohistochemistry ($n = 3$) (*B*). *C*, metatarsals were treated with FGF23 (300 ng/ml) and sKL (300 ng/ml) for 6 days in the presence of 10% of Ihh conditioned media (Ihh-CM) or control conditioned media (Cont-CM) and longitudinal lengths and percent increases in metatarsals were measured ($n = 3–4$). Conditioned media obtained from HEK293 cells overexpressing empty vector were used as Cont-CM. *PZ*: proliferating zone. The figures shown are the representative from at least three independent experiments. The values were expressed as mean ± S.E. *, $p < 0.001$; **, $p < 0.01$; †, $p < 0.05$.

shedding based on a previous report showing that this type of sKL is the predominant sKL in human circulation (27). Interestingly, *in vitro* studies revealed that FGF23 exerted its signals in the presence of sKL in chondrogenic cells. The precise mechanisms whereby sKL mediates FGF23 signaling still need to be elucidated, but the finding that sKL forms a protein complex with FGF23 may raise the possibility that sKL may allow FGF23 to reach and bind to its specific receptors by making a complex with FGF23 in the circulation. Indeed, co-immunoprecipitation analysis revealed that the binding of FGF23 to FGFR3 was enhanced when sKL was present. However, it is still unclear as to whether FGF23/sKL complex is present in the circulation and further analyses are required to determine the significance of this complex in the *in vivo* physiological conditions.

Next, to elucidate the significance of FGF23/sKL signaling in chondrocyte biology, we introduced an *ex vivo* metatarsal organ culture system, which is a widely used procedure to recapitulate *in vivo* bone growth. Using this method, we found a unique phenotype with respect to chondrocyte proliferation such that FGF23/sKL suppressed proliferation in the proliferating zone. The finding that FGF23/sKL impaired chondrocyte proliferation in the proliferating zone led us to speculate that FGF23/sKL may recognize FGFR3 as its receptor because an activating mutation in the *Fgfr3* gene has been shown to result in impaired chondrocyte proliferation (28–30). Based on this, we analyzed whether FGFR3 is involved in FGF23/sKL-mediated suppression of metatarsal growth and provided evidence that FGFR3 is at least in part involved in the FGF23/sKL-mediated action on metatarsal growth. However, given the fact that FGF23/sKL showed a non-significant suppression on the linear growth of metatarsals infected with adenovirus containing microRNA specific for *Fgfr3*, we could not exclude the possibility of the involvement of other types of FGF receptors, although it is still possible that residual expression of FGFR3 may contribute to the suppressive action in FGFR3-knocked down metatarsals. Similar to FGFR3, FGFR1 is abundantly expressed in the growth plate predominantly in perichondrium and hypertrophic chondrocytes, whereas FGFR3 exhibits abundant expression in resting and proliferating chondrocytes, with less expression in hypertrophic chondrocytes (31). The expression profile of FGFR2 is also different from FGFR3, and FGFR2 is mainly expressed in mesenchymal condensation (31). Although previous *in vitro* studies demonstrated the binding of FGF23 to multiple FGF receptors (8, 9), the compartment-specific expression profile of FGFRs in the growth plate would confer a specific binding partner for FGF23 in the presence of sKL such that FGF23 suppresses chondrocyte proliferation in the proliferating zone through the activation of FGFR3.

Multiple pathways have been shown to mediate the effect of FGFR3 activation with respect to the suppression of chondrocyte proliferation. Ihh has been implicated to be the downstream target of FGFR3 activation (21–23) and is well known to play a critical role in chondrocyte proliferation (24, 25). Based on these findings, we tested our speculation that Ihh may be the



FIGURE 10. **Administration of sKL impairs chondrocyte proliferation in *Hyp* mice.** sKL (0.02 mg/kg) was intraperitoneally administered into *Hyp* mice for 3 days from postnatal day 7 and samples were collected on postnatal day 10. *A*, plasma FGF23 concentrations on postnatal day 10 in wild-type and *Hyp* mice (n = 3–4). *B*, body weights of *Hyp* mice on postnatal day 7 and day 10 and percent increases in body weight were calculated (n = 6–7). *C*, gross appearance of the tibia isolated on postnatal day 10 and tibial lengths were determined (n = 6–7). *D*, growth plates of tibiae were histologically analyzed by Hematoxylin and Eosin staining and the lengths of proliferating zones (*PZ*) and hypertrophic zones (*HZ*) were calculated (n = 6–7). *E*, BrdU staining was performed and the ratio of the number of BrdU-positive cells over total cells in the proliferating zone was determined (BrdU index) (n = 6–7). *F*, expression of *Fgf23* in the femur was determined by real-time RT-PCR (n = 3). *G*, expression levels of *Cyp27b1*, *Cyp24a1*, *Slc34a1*, and *Slc34a3* in the kidney were analyzed by real-time RT-PCR (n = 3–5). *H*, plasma levels of phosphate were measured (n = 6–7). The figures shown are the representative from at least three independent experiments. The values were expressed as mean ± S.E. *, $p < 0.001$; **, $p < 0.05$. *ns*, not significant.

downstream target of FGF23/sKL signaling and found that Ihh expression was reduced in the presence of FGF23/sKL and addition of Ihh protein partially reversed the impaired growth of metatarsals treated with FGF23/sKL. Since Ihh protein cannot fully rescue the growth impairment induced by FGF23/sKL signaling, other signals are likely involved in the action of FGF23/sKL on the suppression of chondrocyte proliferation. Because STAT1 has been shown to be activated in response to FGFR3 activation, which in turn results in the inhibition of chondrocyte proliferation (32), a signaling pathway through STAT1 activation may be involved in the FGF23/sKL-induced impairment in chondrocyte proliferation.

In XLH patients, it is well recognized that administration of phosphate and calcitriol is effective to improve linear growth, but is not sufficient to fully reverse impaired growth despite the correction in biochemical markers and rachitic changes (17, 33). This evidence may suggest the existence of factor(s) modulating the linear growth of XLH patients in addition to abnormal phosphate metabolism, and the current findings that FGF23 suppresses chondrocyte proliferation in the presence of sKL may at least in part explain the reason why the correction in serum phosphate levels by administration of phosphate and calcitriol cannot fully regain impaired growth in XLH patients. If this mechanism is operative, the blockade of FGF23 signaling as a strategy for the treatment of XLH patients would be very promising because suppressing FGF23 signaling may have an additional benefit such as enhancing chondrocyte proliferation beyond its capacity to correct phosphate and vitamin D metabolism. Indeed, recent *in vivo* animal studies have provided evidence for the striking effectiveness of the blockade of FGF23 signaling pathways by the anti-FGF23 neutralizing antibody in the improvement of rickets and growth retardation in *Hyp* mice (34).

The significance of sKL in chondrocyte biology in humans remains largely unknown. Recent development in the ELISA system to detect human sKL has revealed that significant amounts of sKL are present in the human circulation (35); however, it is still controversial as to whether sKL in the circulation has any biological functions despite evidence demonstrating the biological function of sKL in animal models (12–14). Nev-

ertheless, the finding that sKL levels are greater in fetal life and childhood than that in adults may suggest that sKL may have more pronounced effects during these times (35–37). Since sKL levels in XLH patients have been shown to be comparable to those of control subjects (36), elevated FGF23 levels in these patients may have a significant impact on the signaling pathways exerted by FGF23/sKL. Our *in vivo* results using supraphysiologic concentrations of sKL may not be used to reach a definitive conclusion regarding the role of physiologic concentrations of sKL in the regulation of chondrocyte biology, but these findings may underline the significance of sKL, especially in fetal life and childhood when sKL levels are elevated and chondrocyte proliferation and maturation are actively operative.

In summary, we demonstrated that FGF23 possessed a noncanonical function where FGF23 suppressed chondrocyte proliferation and maturation in cooperation with sKL independent of phosphate metabolism, and this effect was partly mediated through FGFR3 and involved the suppression of Ihh expression. These lines of evidence add to our growing knowledge regarding signaling networks exerted by FGF23 and provide insights into the unrecognized function of FGF23 signaling that could be important for chondrocyte biology.

Acknowledgments—We thank Drs. R. Nishimura (Osaka University Graduate School of Dentistry), K. Hasegawa (Okayama University Graduate School of Medicine) and A. Guntur (Maine Medical Center Research Institute) for vectors and Drs. A. Imura and Y. Nabeshima (Institute of Biomedical Research and Innovation) for antibodies. We are thankful to Dr. T. Tanaka (Okayama University Graduate School of Medicine) for Hyp mice.

REFERENCES

1. Martin, A., David, V., and Quarles, L. D. (2012) Regulation and function of the FGF23/klotho endocrine pathways. *Physiol. Rev.* **92,** 131–155
2. Bai, X., Miao, D., Li, J., Goltzman, D., and Karaplis, A. C. (2004) Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. *Endocrinology* **145,** 5269–5279
3. Larsson, T., Marsell, R., Schipani, E., Ohlsson, C., Ljunggren, O., Tenenhouse, H. S., Jüppner, H., and Jonsson, K. B. (2004) Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. *Endocrinology* **145,** 3087–3094
4. Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., and Yamashita, T. (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. *J. Clin. Invest.* **113,** 561–568
5. Shimada, T., Urakawa, I., Yamazaki, Y., Hasegawa, H., Hino, R., Yoneya, T., Takeuchi, Y., Fujita, T., Fukumoto, S., and Yamashita, T. (2004) FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. *Biochem. Biophys. Res. Commun.* **314,** 409–414
6. Yamashita, T., Yoshioka, M., and Itoh, N. (2000) Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. *Biochem. Biophys. Res. Commun.* **277,** 494–498
7. Quarles, L. D. (2012) Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. *Nat. Rev. Endocrinol.* **8,** 276–286
8. Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., Fujita, T., Fukumoto, S., and Yamashita, T. (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. *Nature* **444,** 770–774
9. Kurosu, H., Ogawa, Y., Miyoshi, M., Yamamoto, M., Nandi, A., Rosenblatt, K. P., Baum, M. G., Schiavi, S., Hu, M. C., Moe, O. W., and Kuro-o, M. (2006) Regulation of fibroblast growth factor-23 signaling by klotho. *J. Biol. Chem.* **281,** 6120–6123
10. Sitara, D., Kim, S., Razzaque, M. S., Bergwitz, C., Taguchi, T., Schüler, C., Erben, R. G., and Lanske, B. (2008) Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. *PLoS Genet.* **4,** e1000154
11. Wang, H., Yoshiko, Y., Yamamoto, R., Minamizaki, T., Kozai, K., Tanne, K., Aubin, J. E., and Maeda, N. (2008) Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization *in vitro*. *J. Bone Miner. Res.* **23,** 939–948
12. Kurosu, H., Yamamoto, M., Clark, J. D., Pastor, J. V., Nandi, A., Gurnani, P., McGuinness, O. P., Chikuda, H., Yamaguchi, M., Kawaguchi, H., Shimomura, I., Takayama, Y., Herz, J., Kahn, C. R., Rosenblatt, K. P., and Kuro-o, M. (2005) Suppression of aging in mice by the hormone Klotho. *Science* **309,** 1829–1833
13. Liu, H., Fergusson, M. M., Castilho, R. M., Liu, J., Cao, L., Chen, J., Malide, D., Rovira, II, Schimel, D., Kuo, C. J., Gutkind, J. S., Hwang, P. M., and Finkel, T. (2007) Augmented Wnt signaling in a mammalian model of accelerated aging. *Science* **317,** 803–806
14. Doi, S., Zou, Y., Togao, O., Pastor, J. V., John, G. B., Wang, L., Shiizaki, K., Gotschall, R., Schiavi, S., Yorioka, N., Takahashi, M., Boothman, D. A., and Kuro-o, M. (2011) Klotho inhibits transforming growth factor-beta1 (TGF-β1) signaling and suppresses renal fibrosis and cancer metastasis in mice. *J. Biol. Chem.* **286,** 8655–8665
15. Shalhoub, V., Ward, S. C., Sun, B., Stevens, J., Renshaw, L., Hawkins, N., and Richards, W. G. (2011) Fibroblast growth factor 23 (FGF23) and α-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. *Calcif. Tissue Int.* **89,** 140–150
16. De Beur, S. M., Finnegan, R. B., Vassiliadis, J., Cook, B., Barberio, D., Estes, S., Manavalan, P., Petroziello, J., Madden, S. L., Cho, J. Y., Kumar, R., Levine, M. A., and Schiavi, S. C. (2002) Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. *J. Bone Miner. Res.* **17,** 1102–1110
17. Friedman, N. E., Lobaugh, B., and Drezner, M. K. (1993) Effects of calcitriol and phosphorus therapy on the growth of patients with X-linked hypophosphatemia. *J. Clin. Endocrinol. Metab.* **76,** 839–844
18. Liu, S., Vierthaler, L., Tang, W., Zhou, J., and Quarles, L. D. (2008) FGFR3 and FGFR4 do not mediate renal effects of FGF23. *J. Am. Soc. Nephrol.* **19,** 2342–2350
19. Koshimizu, T., Kawai, M., Kondou, H., Tachikawa, K., Sakai, N., Ozono, K., and Michigami, T. (2012) Vinculin functions as regulator of chondrogenesis. *J. Biol. Chem.* **287,** 15760–15775
20. Kawai, M., Breggia, A. C., DeMambro, V. E., Shen, X., Canalis, E., Bouxsein, M. L., Beamer, W. G., Clemmons, D. R., and Rosen, C. J. (2011) The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton. *J. Biol. Chem.* **286,** 14670–14680
21. Naski, M. C., Colvin, J. S., Coffin, J. D., and Ornitz, D. M. (1998) Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. *Development* **125,** 4977–4988
22. Li, C., Chen, L., Iwata, T., Kitagawa, M., Fu, X. Y., and Deng, C. X. (1999) A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. *Hum. Mol. Genet.* **8,** 35–44
23. Chen, L., Li, C., Qiao, W., Xu, X., and Deng, C. (2001) A Ser(365)→Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia. *Hum. Mol. Genet.* **10,** 457–465
24. Vortkamp, A., Lee, K., Lanske, B., Segre, G. V., Kronenberg, H. M., and Tabin, C. J. (1996) Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. *Science* **273,** 613–622
25. Kobayashi, T., Soegiarto, D. W., Yang, Y., Lanske, B., Schipani, E., McMahon, A. P., and Kronenberg, H. M. (2005) Indian hedgehog stimulates periarticular chondrocyte differentiation to regulate growth plate length independently of PTHrP. *J. Clin. Invest.* **115,** 1734–1742
26. Faul, C., Amaral, A. P., Oskouei, B., Hu, M. C., Sloan, A., Isakova, T.,

Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., Mundel, P., Morales, A., Scialla, J., Fischer, M., Soliman, E. Z., Chen, J., Go, A. S., Rosas, S. E., Nessel, L., Townsend, R. R., Feldman, H. I., St John Sutton, M., Ojo, A., Gadegbeku, C., Di Marco, G. S., Reuter, S., Kentrup, D., Tiemann, K., Brand, M., Hill, J. A., Moe, O. W., Kuro-O, M., Kusek, J. W., Keane, M. G., and Wolf, M. (2011) FGF23 induces left ventricular hypertrophy. *J. Clin. Invest.* **121,** 4393–4408

27. Imura, A., Iwano, A., Tohyama, O., Tsuji, Y., Nozaki, K., Hashimoto, N., Fujimori, T., and Nabeshima, Y. (2004) Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. *FEBS Lett.* **565,** 143–147
28. Chen, L., Adar, R., Yang, X., Monsonego, E. O., Li, C., Hauschka, P. V., Yayon, A., and Deng, C. X. (1999) Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. *J. Clin. Invest.* **104,** 1517–1525
29. Wang, Y., Spatz, M. K., Kannan, K., Hayk, H., Avivi, A., Gorivodsky, M., Pines, M., Yayon, A., Lonai, P., and Givol, D. (1999) A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. *Proc. Natl. Acad. Sci. U.S.A.* **96,** 4455–4460
30. Segev, O., Chumakov, I., Nevo, Z., Givol, D., Madar-Shapiro, L., Sheinin, Y., Weinreb, M., and Yayon, A. (2000) Restrained chondrocyte proliferation and maturation with abnormal growth plate vascularization and ossification in human FGFR-3(G380R) transgenic mice. *Hum. Mol. Genet.* **9,** 249–258
31. Ornitz, D. M., and Marie, P. J. (2002) FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. *Genes Dev.* **16,** 1446–1465
32. Sahni, M., Ambrosetti, D. C., Mansukhani, A., Gertner, R., Levy, D., and Basilico, C. (1999) FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. *Genes Dev.* **13,** 1361–1366
33. Chesney, R. W., Mazess, R. B., Rose, P., Hamstra, A. J., DeLuca, H. F., and Breed, A. L. (1983) Long-term influence of calcitriol (1,25-dihydroxyvitamin D) and supplemental phosphate in X-linked hypophosphatemic rickets. *Pediatrics* **71,** 559–567
34. Aono, Y., Yamazaki, Y., Yasutake, J., Kawata, T., Hasegawa, H., Urakawa, I., Fujita, T., Wada, M., Yamashita, T., Fukumoto, S., and Shimada, T. (2009) Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. *J. Bone Miner. Res.* **24,** 1879–1888
35. Yamazaki, Y., Imura, A., Urakawa, I., Shimada, T., Murakami, J., Aono, Y., Hasegawa, H., Yamashita, T., Nakatani, K., Saito, Y., Okamoto, N., Kurumatani, N., Namba, N., Kitaoka, T., Ozono, K., Sakai, T., Hataya, H., Ichikawa, S., Imel, E. A., Econs, M. J., and Nabeshima, Y. (2010) Establishment of sandwich ELISA for soluble α-Klotho measurement: Age-dependent change of soluble α-Klotho levels in healthy subjects. *Biochem. Biophys. Res. Commun.* **398,** 513–518
36. Carpenter, T. O., Insogna, K. L., Zhang, J. H., Ellis, B., Nieman, S., Simpson, C., Olear, E., and Gundberg, C. M. (2010) Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. *J. Clin. Endocrinol. Metab.* **95,** E352–357
37. Ohata, Y., Arahori, H., Namba, N., Kitaoka, T., Hirai, H., Wada, K., Nakayama, M., Michigami, T., Imura, A., Nabeshima, Y., Yamazaki, Y., and Ozono, K. (2011) Circulating levels of soluble alpha-Klotho are markedly elevated in human umbilical cord blood. *J. Clin. Endocrinol. Metab.* **96,** E943–947

Clin Pediatr Endocrinol 2013; 22(1), 9–14
Copyright© 2013 by The Japanese Society for Pediatric Endocrinology

Original Article

Treatment of Hypophosphatemic Rickets with Phosphate and Active Vitamin D in Japan: A Questionnaire-based Survey

Makoto Fujiwara[1], Noriyuki Namba[1], Keiichi Ozono[1], Osamu Arisaka[2], Susumu Yokoya[3], and Committee on Drugs, Japanese Society for Pediatric Endocrinology*

[1]*Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan*

[2]*Department of Pediatrics, Dokkyo Medical University School of Medicine, Tochigi, Japan*

[3]*Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan*

Abstract. Hereditary hypophosphatemic rickets represented by X-linked hypophosphatemic rickets (XLH) is a rare disorder characterized by hypophosphatemia, elevated alkaline phosphatase (ALP) and undermineralization of bone. Active vitamin D and phosphate are administered to correct hypophosphatemia and elevation of ALP. Overtreatment with phosphate leads to secondary hyperparathyroidism, and a large dose of active vitamin D has a risk of hypercalciuria. To understand the situation concerning treatment of patients with hereditary hypophosphatemic rickets in Japan, we conducted a questionnaire survey of pediatric endocrinologists. Answers were obtained from 53 out of 68 hospitals where the pediatric endocrinologists worked. One hundred and thirty-five patients were treated in 28 hospitals during November 2009 and May 2010; 126 patients suffered from hereditary hypophosphatemic rickets, and 9 had hypophosphatemia caused by other miscellaneous reasons. The distribution of patient age was as follows: 27 (21%) were between 6 mo and 6 yr of age, 39 (31%) were between 6 and 12 yr of age, and 60 (48%) were more than 12 yr of age. Active vitamin D was given to 123 patients, and phosphate was given to 106 patients. As for the dose of phosphorus, 37.2–58.1 mg/kg/d was given divided into 2 to 6 aliquots. There were various control targets of treatment, including serum phosphate, serum ALP, rachitic change, urinary Ca/Cr, parathyroid hormone and growth. It is very important to avoid side effects of these treatments. No evidence is available about the optimal dose of phosphate or number of administrations in the treatment of patients with hypophosphatemic rickets. Although there is a recommendation for clinical management of patients with hypophosphatemic rickets, we should set a clinical guideline for it in Japan.

Key words: hypophosphatemia, phosphaturia, rickets, active vitamin D, phosphate

Received: June 22, 2012
Accepted: October 22, 2012
Correspondence: Dr. Keiichi Ozono, Department of Pediatrics, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan
E-mail: keioz@ped.med.osaka-u.ac.jp

* Member list of the Department of Molecular Endocrinology, National Research Institute for Child Health and Development: Osamu Arisaka, Susumu Yokoya, Shin Amemiya, Toshiaki Tanaka, Tomonobu Hasegawa, Hiroyuki Tanaka, Syohei Harada.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-ncnd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.

Introduction

Rickets is a disorder of calcification in chondrocytes and bone characterized by accumulation of unmineralized bone, termed osteoid. Characteristic X-ray findings such as cupping, flaring, and fraying strongly suggest

rickets, although metaphyseal dysplasia must be ruled out. The main causes of rickets are vitamin D deficiency and hereditary hypophosphatemic rickets. Hypophosphatemia and elevated levels of alkaline phosphatase (ALP) are associated with both vitamin D-deficient and hereditary hypophosphatemic rickets.

Hereditary hypophosphatemic rickets is classified mainly into 4 entities based on mode of inheritance and urinary excretion of calcium (1, 2). Recently, the genes responsible for these forms of hereditary hypophosphatemic rickets have been identified. Autosomal dominant hypophosphatemic rickets (ADHR, MIM 193100) is a rare disease characterized by low levels of serum phosphate and elevated levels of ALP and phosphaturia and is inherited in an autosomal dominant fashion. In 2000, genetic analysis of families with the disease successfully identified that the *FGF23* (fibroblast growth factor 23) gene is responsible for the disease (3). Now FGF23 is recognized as a hormone that plays a central part in regulation of the serum phosphate concentration, and its abnormality is involved in many cases of hypophosphatemic rickets (4, 5). In ADHR, since the mutant FGF23 is resistant to degradation, its concentration is elevated in serum. Thus, this mutation is a gain-of-function type. FGF23 works as a phosphaturic factor after binding to FGFR1 and its co-receptor, klotho, in the kidney and reduces serum phosphate concentrations (6). In addition, FGF23 decreases the production of 1, 25-dihydroxyvitamin D [1,25$(OH)_2$D] in renal tubules (7). In turn, 1, 25$(OH)_2$D and phosphate increase the expression of FGF23 (8). Therefore, administration of active vitamin D and phosphate may exert biphasic effects, i.e., acute increase in phosphate levels followed by decrease in phosphate levels associated with an increase in FGF23 levels.

Autosomal recessive hypophosphatemic rickets (ARHR1, MIM 241520) is also a rare disease in which hypophosphatemia and rickets are observed. The causal gene is *DMP1* (dentine matrix protein 1), and its expression is observed in osteocytes and osteoblasts (9). *ENPP1* is a newly identified causal gene (ARHR2, MIM 613312) (10, 11). The *ENPP1* gene encodes ectonucleotide pyrophosphatase/phosphodiesterase 1 and is also responsible for generalized arterial calcification of infancy (12). Although the mechanism remains obscure, FGF23 is elevated in both types of ARHR and reduces serum phosphate concentrations (13). In Japan, two single families are reported to have abnormalities in each of these gene (14, 15).

Hereditary hypophosphatemic rickets with hypercalciuria (HHRH, MIM 241530) is a rare autosomal recessive disease characterized by hypophosphatemia and hypercalciuria. It is caused by *SLC34A3*, which encodes the type IIc sodium-dependent phosphate co-transporter (NaPi-IIc), a transporter for reabsorption of phosphate in the proximal renal tubules (16–18). The administration of phosphate alone ameliorates hypophosphatemia and hypercalciuria in HHRH.

X-linked hypophosphatemic rickets (XLH, MIM 307800) is the most frequent and prototype form of hypophosphatemic rickets in pediatric practice. In 1995, the gene responsible for the disease was identified as *PHEX* (phosphate regulating gene with homologies to endopeptidases on the X chromosome) (19). To date, over 200 mutations have been found in the *PHEX* gene and listed in the PHEXdb, PHEX Locus Database (http://www.phexdb.mcgill.ca). Patients with XLH are treated with active vitamin D and phosphate buffer. However, phosphate buffer is not available as a prescribed medicine in Japan. In addition, treatment with vitamin D and phosphate buffer is not an absolute cure for the disease, though a recommendation for treatment has been published (20).

Hypophosphatemic rickets is also caused by impaired function of renal tubules and tumors that produce FGF23. Malfunction of renal tubules sometimes involves reabsorption of essential nutrients or minerals other than phosphate and is called Fanconi syndrome (MIM 134600, 613388, or acquired). The acquired form



Fig. 1 Patient background. (A) The cause of hypophosphatemia in all patients. (B) The ages of the patients with hereditary hypophosphatemic rickets.



Fig. 2 Treatment for patients with hereditary hypophosphatemic rickets.

is called tumor-induced osteomalacia (TIO) and is rare in childhood (21–23).

We attempted to clarify how hypophosphatemic rickets is actually treated in Japan. To this end, we sent questionnaires concerning the experience of treatment of patients with hypophosphatemic rickets and the actual procedures.

Material and Methods

We sent questionnaires by mail to 68 hospitals where 80 pediatric endocrinologists approved by the Japanese Society of Pediatric Endocrinology worked in 2010. Survey subjects are patients who show hypophosphatemia for more than 6 mo. The questionnaire includes the number patients, patient profiles such as age and sex, hereditary pattern, type of medicine, and dose of phosphate including minimum and maximum dose and frequency.

Results

Responses to the questionnaire were obtained from 53 out of 68 (78% of total) hospitals to which the questionnaires were sent. A total of 135 patients were treated in 28 (53% of response) hospitals during November 2009 and May 2010; 126 patients suffered from hereditary phosphatemic rickets, and 9 had hypophosphatemia caused by other miscellaneous reasons (Fig. 1-A). In this paper, we focused on the 126 patients who had hereditary hypophosphatemic rickets. Patient profiles were as follows: 27 (21%) patients were between 6 mo and 6 yr of age, 39 (31%) patients were between 6 and 12 yr of age, and 60 (48%) patients were more than 12 yr of age (Fig. 1-B). Active vitamin D and phosphate were administered to 123 and 106 patients, respectively. Twelve patients were treated with growth hormone (Fig. 2). The means of the minimum and maximum doses of phosphorus were 37.2 and 58.1 mg/kg/d, respectively, and the dosed were administered in 2 to 6 aliquots (Table 1). Efficacy of the treatment was monitored by various factors including serum phosphate, ALP, intact PTH, urinary Ca/Cr, radiologic features, and growth. In particular, serum phosphate levels were monitored by 18 physicians. The target levels were set between 2 and 3.5 mg/dl. Serum ALP was also used as a marker by 17 physicians. The target levels varied from normal to 2,000 IU/l. In addition, 7 physicians employed intact PTH with target levels varying from normal to twice the normal level.

Table 1 Phosphorus dose and dose frequency

Dose (mg/kg/d)

	Minimum dose	Maximum dose
Mean	37.2	58.1
Range	15–100	30–120

Dose frequency

Physicians that adjust dose frequency: 17					
	2 times/d	3 times/d	4 times/d	5 times/d	6 times/d
Minimum	3	9	4	1	–
Maximum	–	1	10	2	4
Physicians that use a fixed frequency: 7					
	2 times/d	3 times/d	4 times/d	5 times/d	6 times/d
	1	–	5	–	1

Discussion

Hereditary hypophosphatemic rickets is often associated with bone deformity, bone pain and growth retardation. Bone deformity sometimes requires surgery for correction. At present, there is no curative therapy for XLH, and active vitamin D and phosphate are administered to correct hypophosphatemia and elevation of ALP (24). However, normalization of the serum phosphate concentration is difficult due to elevation of FGF23, leading to increased excretion of phosphate into urine (25, 26). Insufficient treatment is associated with growth retardation (27). On the other hand, overtreatment with phosphate leads to secondary hyperparathyroidism, and large doses of active vitamin D increase the risk of hypercalciuria (20). Though a recommendation for XLH treatment has been published, it is far from complete cure. Moreover, since phosphate is not a prescribed medicine in Japan, the buffer has to be prepared in the hospital dispensary.

To understand the situation concerning treatment of patients with hereditary hypophosphatemic rickets in Japan, we conducted a questionnaire survey among pediatric endocrinologists. The percentage of the patients with XLH covered by this questionnaire is unclear, but in Japan, it is rare that pediatric nephrologists alone treat patients with XLH.

In the survey, 103 to 106 (82 to 84%) of 123 patients with hereditary hypophosphatemic rickets were treated with both active vitamin D and phosphate. At least 17 (13%) of the patients with hereditary hypophosphatemic rickets were treated with active vitamin D only. Twelve (10%) of the patients with hereditary hypophosphatemic rickets were treated with growth hormone, probably because they had short stature and growth hormone deficiency. The criteria for adjusting the dose of active vitamin D or phosphate buffer were various. One problem is that both serum phosphate and ALP values are age dependent, and normalization of serum phosphate levels and ALP was difficult. X-ray findings are not quantitative, and growth is long term. Thus, these indices are difficult to use in the short term. It is also critical to avoid side effects of the treatment. Thus, the doses of active vitamin D and phosphate should be reduced when hypercalciuria and secondary hyperparathyroidism are observed, respectively.

No information is available concerning the most effective dose of phosphate and how many times it should be administered in the treatment

of patients with hypophosphatemic rickets. In Pediatric Endocrinology and Inborn Errors of Metabolism (28), 40–100 mg/kg/d, divided into 4 to 6 doses, is recommended. However, adherence tends to become poor when short intervals are selected. In this survey, 37.2–58.1 mg/kg/d of phosphorus divided into 3 to 4 doses was most common. Thus, most physicians seemed to treat XLH patients within the recommended way of treatment in the actual clinical setting.

Acknowledgement

We are grateful to all the doctors who responded to the questionnaire.

References

1. Alizadeh Naderi AS, Reilly RF. Hereditary disorders of renal phosphate wasting. Nat Rev Nephrol 2010;6:657–65. [Medline] [CrossRef]
2. Carpenter TO. The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 2012;30:1–9. [Medline] [CrossRef]
3. The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in *FGF23*. Nat Genet 2000;26:345–8. [Medline] [CrossRef]
4. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, *et al.* Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002;87:4957–60. [Medline] [CrossRef]
5. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001;60:2079–86. [Medline] [CrossRef]
6. Gattineni J, Baum M. Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol 2010;25:591–601. [Medline] [CrossRef]
7. Perwad F, Portale AA. Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23. Mol Cell Endocrinol 2011;347:17–24. [Medline] [CrossRef]
8. Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF23: regulation by phosphate? Bone 2004;35:1192–9. [Medline] [CrossRef]
9. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, *et al.* Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006;38:1310–5. [Medline] [CrossRef]
10. Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, *et al.* Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the *ENPP1* gene. Am J Hum Genet 2010;86:273–8. [Medline] [CrossRef]
11. Lorenz-Depiereux B, Schnabel D, Tiosano D, Häusler G, Strom TM. Loss-of-function *ENPP1* mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 2010;86:267–72. [Medline] [CrossRef]
12. Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Höhne W, *et al.* Mutations in *ENPP1* are associated with 'idiopathic' infantile arterial calcification. Nat Genet 2003;34:379–81. [Medline] [CrossRef]
13. Martin A, Liu S, David V, Li H, Karydis A, Feng JQ, *et al.* Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 2011;25:2551–62. [Medline] [CrossRef]
14. Koshida R, Yamaguchi H, Yamasaki K, Tsuchimochi W, Yonekawa T, Nakazato M. A novel nonsense mutation in the DMP1 gene in a Japanese family with autosomal recessive hypophosphatemic rickets. J Bone Miner Metab 2010;28:585–90. [Medline] [CrossRef]
15. Saito T, Nishii Y, Yasuda T, Ito N, Suzuki H, Igarashi T, *et al.* Familial hypophosphatemic rickets caused by a large deletion in PHEX gene. Eur J Endocrinol 2009;161:647–51. [Medline] [CrossRef]
16. Segawa H, Kaneko I, Takahashi A, Kuwahata M, Ito M, Ohkido I, *et al.* Growth-related renal type II Na/Pi cotransporter. J Biol Chem 2002;277:19665–72. [Medline] [CrossRef]

17. Lorenz-Depiereux B, Benet-Pages A, Eckstein G, Tenenbaum-Rakover Y, Wagenstaller J, Tiosano D, *et al.* Hereditary Hypophosphatemic Rickets with Hypercalciuria is Caused by Mutations in the Sodium-Phosphate Cotransporter Gene *SLC34A3*. Am J Hum Genet 2006;78:193–201. [Medline] [CrossRef]
18. Bergwitz C, Roslin NM, Tieder M, Loredo-Osti JC, Bastepe M, Abu-Zahra H, *et al.* *SLC34A3* Mutations in Patients with Hereditary Hypophosphatemic Rickets with Hypercalciuria Predict a Key Role for the Sodium-Phosphate Cotransporter NaPi-IIc in Maintaining Phosphate Homeostasis. Am J Hum Genet 2006;78:179–92. [Medline] [CrossRef]
19. Francis F, Hennig S, Korn B, Reinhardt R, Jong PD, Poustka A, *et al.* A gene (*PEX*) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 1995;11:130–6. [Medline] [CrossRef]
20. Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res 2011;26:1381–8. [Medline] [CrossRef]
21. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, *et al.* Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98:6500–5. [Medline] [CrossRef]
22. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, *et al.* Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656–63. [Medline] [CrossRef]
23. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocrine-Related Cancer 2011;18:R53–77. [Medline] [CrossRef]
24. Kienitz T, Ventz M, Kaminsky E, Quinkler M. Novel PHEX nonsense mutation in a patient with X-linked hypophosphatemic rickets and review of current therapeutic regimens. Exp Clin Endocrinol Diabetes 2011;119:431–5. [Medline] [CrossRef]
25. Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab 2010;95:1846–50. [Medline] [CrossRef]
26. Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, *et al.* Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab 2010;95:E352–7. [Medline] [CrossRef]
27. Quinlan C, Guegan K, Offiah A, Neill RO, Hiorns MP, Ellard S, *et al.* Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment. Pediatr Nephrol 2012;27:581–8. [Medline] [CrossRef]
28. Roth KS, Ward RJ, Chan JC, Sarafoglou K. Disorders of Calcium, Phosphate, and Bone Metabolism. In: Sarafoglou K, Hoffmann GF, Roth KS, editors. Pediatric Endocrinology and Inborn Errors of Metabolism. New York: McGraw Hill;2009.p.619–64.

Original Paper

HORMONE RESEARCH IN PÆDIATRICS

Horm Res Paediatr
DOI: 10.1159/000357142

Received: July 30, 2013
Accepted: November 5, 2013
Published online: February 26, 2014

Serum Fibroblast Growth Factor 23 Is a Useful Marker to Distinguish Vitamin D-Deficient Rickets from Hypophosphatemic Rickets

Takuo Kubota[a, b] Taichi Kitaoka[a] Kohji Miura[a] Makoto Fujiwara[a] Yasuhisa Ohata[a] Yoko Miyoshi[a] Keiko Yamamoto[a] Shinji Takeyari[c] Takehisa Yamamoto[c] Noriyuki Namba[a] Keiichi Ozono[a]

[a] Department of Pediatrics, Graduate School of Medicine, and [b] First Department of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Osaka University, and [c] Department of Pediatrics, Minoh City Hospital, Osaka, Japan

Key Words
Vitamin D · Fibroblast growth factor 23 · Rickets · Hypophosphatemia · Children

Abstract
Background/Aims: Vitamin D-deficient rickets (DR) has recently re-emerged among developed countries. Vitamin D deficiency can influence biochemical results of patients with fibroblast growth factor 23 (FGF23)-related hereditary hypophosphatemic rickets (HR), making differential diagnosis difficult. In the present study we evaluated the utility of serum FGF23 levels in the diagnosis of DR and during its treatment. ***Methods:*** The study group comprised 24 children with DR and 8 children with HR. Serum FGF23 levels and bone metabolism-related measurements were assessed. ***Results:*** Serum FGF23 levels in patients with DR were less than 19 pg/ml, while those in patients with HR were more than 57 pg/ml. There were significant differences in serum levels of calcium, phosphate, parathyroid hormone, and 1,25-dihydroxyvitamin D, as well as tubular maximum phosphate reabsorption per glomerular filtration rate between patients with DR and HR, but these values were not fully mutually exclusive. In addition, serum FGF23 and phosphate levels were increased following treatment. ***Conclusion:*** Serum FGF23 level is the most critical biochemical marker for distinguishing DR from HR and might be a good indicator of biochemical response to the intervention. Serum FGF23 levels show utility for the diagnosis of DR and in the assessment of its response to treatment.
© 2014 S. Karger AG, Basel

Introduction

Rickets is caused by defective mineralization in the growth plate of cartilage and in the matrix of bone in a growing child [1, 2]. Bowed legs, enlargement of the wrists and knees, rachitic rosary, craniotabes, growth retardation, delayed initiation of walking, and waddling gait are often associated with rickets. Diagnosis of rickets requires radiographic signs such as cupping, splaying, or fraying in the metaphysis of a long bone.

The most common cause of rickets is vitamin D deficiency, although genetic or acquired disorders of the gut, liver, kidney, and metabolism of vitamin D can cause rickets [2]. Increased numbers of patients with vitamin D deficiency have been reported among children in recent years throughout the world [3–5], including Japan [6–9]. Circulating 25-hydroxyvitamin D [25(OH)D] concentration is the best clinical indicator of vitamin D repletion in the body. Vitamin D deficiency is diagnosed by the mea-

KARGER
E-Mail karger@karger.com
www.karger.com/hrp

© 2014 S. Karger AG, Basel
1663–2818/14/0000–0000$39.50/0

Keiichi Ozono, MD, PhD
2-2 Yamadaoka
Suita, Osaka 565-0871 (Japan)
E-Mail keioz@ped.med.osaka-u.ac.jp

Downloaded by:

surement of serum 25(OH)D concentration below 20 ng/ml in adults [10, 11]. In addition, many experts have commonly proposed a cutoff value of 20 ng/ml for serum 25(OH)D concentration to designate vitamin D deficiency in children [12, 13]. Treatment of vitamin D deficiency with native vitamin D or active vitamin D is effective for the correction of rickets [8, 14].

X-linked hypophosphatemic rickets (HR) is the most common form of heritable rickets and is manifested by fibroblast growth factor 23 (FGF23) excess and renal phosphate wasting [15, 16]. Clinical and radiographic features are mostly similar to vitamin D-deficient rickets (DR). Biochemical findings include hypophosphatemia and low-to-normal circulating 1,25-dihydroxyvitamin D [1,25$(OH)_2$D]. Serum concentrations of parathyroid hormone (PTH) are usually normal or modestly elevated in some cases. Other forms of FGF23-related hereditary HR have been described, including an autosomal dominant form caused by mutations in FGF23 and autosomal recessive forms caused by mutations in dentin matrix protein 1 and in ectonucleotide pyrophosphatase/phosphodiesterase 1. The prevalence of these forms of HR appears much less than that of X-linked HR. Serum FGF23 concentrations are increased in patients with HR [17, 18]. FGF23 decreases serum phosphate concentrations by the inhibition of renal proximal tubular phosphate reabsorption and the suppression of 25(OH)D-1α-hydroxylase [19]. Vitamin D and phosphate are necessary for the treatment of HR [15, 20].

In collaboration with other institutes, we previously reported on the diagnostic utility of serum FGF23 measurement in patients with hypophosphatemia [21]. However, it remains unclear whether serum FGF23 measurement is useful for differentiating DR and HR, especially in the case of comorbidity of HR plus vitamin D deficiency. Thus, in the current study, we report the diagnostic utility of serum FGF23 measurements to distinguish patients with DR from those with HR.

Subjects and Methods

Subjects

This study included 32 patients who attended Osaka University Hospital or Minoh City Hospital (Osaka, Japan) from January 2003 through June 2012 and who were diagnosed with DR or HR based on clinical, laboratory, and radiographic findings, as well as clinical course. In detail, the diagnostic criteria of DR included radiographic signs such as cupping, splaying, or fraying in the metaphysis of a long bone, high serum levels of alkaline phosphatase (AP) and PTH, and low 25(OH)D levels. Vitamin D deficiency was defined as serum 25(OH)D levels less than 20 ng/ml [13]. The diagnosis of DR was confirmed by no recurrence of rickets after discontinuation of treatment. The diagnostic criteria of HR included radiographic signs such as cupping, splaying, or fraying in the metaphysis of a long bone, low serum phosphate concentrations, and tubular maximum phosphate reabsorption per glomerular filtration rate (TmP/GFR), high AP levels, and normal levels of PTH, 1,25$(OH)_2$D, and 25(OH)D. Although 2 patients did not meet the criteria of HR due to low 25(OH)D levels, they were diagnosed with HR because of high FGF23 levels and resistance to α-calcidol treatment. Other disorders which could develop rickets were excluded, including malabsorption, liver and renal tubular diseases, parathyroid disorders, type I and II vitamin D-dependent rickets, hypophosphatasia, primary disorders of bone matrix, drug-induced mineralization defects, and tumors. Twenty-four patients (11 boys, 13 girls) were diagnosed with DR and 8 (2 boys, 6 girls) with HR. Seven of the 8 patients with HR were sporadic, while 1 patient inherited HR from her mother. Physical examinations were made, and blood and urine samples were taken. Radiography demonstrated rachitic signs in the metaphysis of a long bone in all the patients. Complaints, feeding type before solid food, restricted and/or unbalanced diet, and sunlight exposure were evaluated for DR patients. Dietary content and sun exposure were based on information obtained from parents or guardians. When patients were not given some foods because of concern about allergy, it was considered as a restricted diet. When patients did not take certain foods, it was considered as an unbalanced diet. Playing outside twice a week or less was regarded as insufficient sun exposure. Laboratory data without serum FGF23 levels of 3 DR patients and those with serum FGF23 levels of 2 HR patients were included in previous publications by our group [9, 21]. Measurement of serum FGF23 levels was approved by the institutional review board of Osaka University Hospital and written informed consent was obtained from the parents or guardians of the patients. Patients with DR were treated with α-calcidol suspension because neither cholecalciferol nor ergocalciferol suspension is available on prescription or on the market in Japan.

Measurements

Laboratory measurements included serum levels of calcium (reference range: 8.4–10.0 mg/dl), phosphate (4.2–6.2 mg/dl for the age of 1 year), AP (353–1,009 U/l for the age of 1 year), PTH (10–60 pg/ml), 1,25$(OH)_2$D (20–60 pg/ml), 25(OH)D (the lower limit, 20 ng/ml [13]), and FGF23 (10–50 pg/ml for adults [21]), as well as TmP/GFR (2.7–6.3 mg/dl for the ages 1–24 months [22]) and urine calcium/creatinine ratio (U-Ca/Cr). TmP/GFR was calculated from the formula: TmP/GFR = serum phosphate – urine phosphate × serum creatinine/urine creatinine [23]. Serum 25(OH)D levels were measured in 3 out of 8 with patients with HR. Serum FGF23 levels were measured by an ELISA method that recognizes only full-length biologically active FGF23 (Kainos Laboratories, Japan). The lowest reportable value of FGF23 was 10 pg/ml. Serum 25(OH)D levels were measured by a competitive immunoluminometric direct assay (LIAISON 25OH Vitamin D TOTAL Assay; DiaSorin, USA, 20 samples) and by competitive protein-binding assays (Mitsubishi Chemical Medience, Japan, 6 samples; BML, Japan, 1 sample) because of differences of assay costs.

Statistics

Data were analyzed by a Mann-Whitney U test, ROC analysis, or paired t test using JMP (SAS Institute, USA) and SPSS (IBM SPSS, USA) statistical software.

Downloaded by:
Osaka University
133.1.67.196 - 3/10/2014 6:52:07 AM



Fig. 1. Biochemical measurements of patients with DR and HR before treatment. Note that only the serum FGF23 level is exclusive between DR and HR. The data are presented as box plots. $p < 0.01$ for calcium, phosphate, PTH, $1{,}25(OH)_2D$, FGF23, and TmP/GFR. Dashed and dotted lines are the upper and lower limit of reference ranges, respectively.

Results

Clinical Features of DR Patients

Clinical features, including complaints, feeding type before solid foods, restricted and/or unbalanced diet restriction, and sunlight exposure were evaluated in the 24 DR patients. Complaints consisted of bowed legs (n = 18, 75%), elevated serum AP level (n = 5, 21%), and convulsions (n = 1, 4%). Feeding type before solid food was exclusively breast milk (n = 21, 89%) and breast plus formula milk (n = 1, 4%). Twelve patients (50%) had a restricted and/or unbalanced diet. There were 6 patients (25%) with insufficient sun exposure.

Characteristics of DR and HR Patients

There were no differences in age, height, and weight between DR and HR patients. Age was 17 ± 7 (mean ± SD) months, height was –1.3 ± 1.5 SD score (SDS), and weight was –0.5 ± 1.3 SDS in DR patients compared to age 21 ± 8 months, height –1.9 ± 1.0 SDS, and weight –0.1 ± 0.8 SDS in HR patients.

Utility of Serum FGF23 Levels to Distinguish HR and DR Patients

Laboratory findings of DR and HR patients were determined before treatment (fig. 1). Serum calcium concentration was lower in patients with DR than those

Downloaded by:

Table 1. ROC analysis of biochemical data for the diagnosis of DR and HR

Measurement	AUC	SE	95% CI	p
FGF23	1.00	0.00	1.00, 1.00	<0.01
25(OH)D	0.82	0.11	0.61, 1.04	0.09
Calcium	0.57	0.20	0.17, 0.96	0.72
Phosphate	0.14	0.09	−0.03, 0.32	0.06
$1,25(OH)_2D$	0.12	0.11	−0.10, 0.34	<0.05
PTH	0.11	0.08	−0.05, 0.27	<0.05
TmP/GFR	0.02	0.03	−0.04, 0.09	<0.05

Serum FGF23 level is the most significant measurement for distinguishing patients with DR from those with HR on ROC analysis (1 = DR, 0 = HR).

with HR, although they stayed within the reference range (8.4–10.0 mg/dl) in most patients with DR (fig. 1). Serum phosphate concentration was higher in patients with DR than those with HR. Some patients with DR had reference serum phosphate concentrations (4.2–6.2 mg/dl for the age of 1 year). Serum levels of PTH and $1,25(OH)_2D$ and TmP/GFR were increased in patients with DR compared to those with HR. While there were significant differences in serum levels of calcium, phosphate, PTH, and $1,25(OH)_2D$, as well as TmP/GFR, between patients with DR and with HR, a clear overlap of the data existed between the two groups. Of note, a patient with HR had an obvious increase in serum PTH (145 pg/ml) and $1,25(OH)_2D$ (110 pg/ml). All serum 25(OH)D levels in patients with DR were less than 18 ng/ml. Patients with HR had serum 25(OH)D levels of 8.2, 14.1, and 25.2 ng/ml before the treatment, indicating the presence of vitamin D deficiency in at least 2 patients with HR. Serum FGF23 levels were different and, notably, exclusive between patients with DR and HR. Serum FGF23 levels in all patients with DR were 18 pg/ml or less, while 72% had levels less than 10 pg/ml (reference range for adults: 10–50 pg/ml [21]). In contrast, serum FGF23 levels in patients with HR were 58 pg/ml and more. These results indicate that the measurement of serum FGF23 levels is useful to distinguish patients with DR from those with HR. There were no differences in serum AP levels and U-Ca/Cr between patients with DR and HR. Furthermore, ROC analysis showed the AUC of serum FGF23 had a more significant p value among the measurements, including TmP/GFR, PTH, and $1,25(OH)_2D$ (table 1). These results suggest that serum FGF23 measurements may be more useful compared to measurements including TmP/GFR, PTH, and $1,25(OH)_2D$ to discriminate patients with DR from those with HR.

Response of Serum FGF23 Levels to Intervention among DR Patients

Laboratory data of patients with DR were determined in the period before intervention and 1–3 months following treatment using α-calcidol combined with lifestyle advice for adequate sun exposure and diet (fig. 2). Both data before and 1–3 months after intervention were obtained in 6 patients with DR. Serum levels of FGF23, as well as phosphate, PTH, and AP, were significantly changed after intervention compared to those before. In addition, percent increases in FGF23 levels after intervention were positively correlated with those in serum phosphate concentrations ($p < 0.05$, $r = 0.87$; data not shown), and tended to be inversely correlated with percent decreases in PTH levels ($p = 0.06$, $r = -0.79$). Serum calcium and $1,25(OH)_2D$ levels, TmP/GFR, and U-Ca/Cr were not obviously changed by intervention. These results suggest that serum FGF23 level might be a good indicator of biochemical response to treatment and for lifestyle advice to patients with DR.

Discussion

Our study demonstrated that serum FGF23 is clearly suppressed in infants with DR. Thus, it is suggested that FGF23 is a useful marker to distinguish DR from HR, although not all patients with DR require FGF23 measurement. Indeed, serum levels of calcium, phosphate, PTH, and $1,25(OH)_2D$, as well as TmP/GFR, are also useful to distinguish DR from HR; however, only serum FGF23 levels were mutually exclusive between DR and HR. In addition, serum FGF23 levels were increased following treatment with α-calcidol and lifestyle advice on sun exposure and diet, suggesting that serum FGF23 level might be a good indicator of biochemical response to intervention. At least 2 patients with HR had low serum 25(OH)D levels and one of them had high PTH and $1,25(OH)_2D$ levels. These results suggest hypovitaminosis D may influence the biochemical data of patients with HR and make diagnosis of HR difficult. On the other hand, FGF23 remained high in patients with HR even when hypovitaminosis D is a complicating factor.

Serum PTH levels in patients with HR are usually normal or modestly elevated in some case [16]. However, given that patients with HR may have low serum 25(OH)D

Downloaded by:
Osaka University
133.1.67.196 - 3/10/2014 6:52:07 AM



Fig. 2. Response of biochemical measurements to intervention in patients with DR. Serum levels of phosphate, PTH, AP, and FGF23 were significantly changed after the intervention compared to those before. $p < 0.01$ for phosphate, AP, and FGF23; $p < 0.05$ for PTH. Dashed and dotted lines are the upper and lower limit of reference ranges, respectively.

levels, clinicians should bear in mind that high serum PTH levels do not preclude a possibility of HR. In this study, there was a clear and exclusive difference in serum FGF23 levels between infants with DR and HR. These results indicate that a finding of the decrease in serum FGF23 levels is useful for differentiating DR from HR.

It is unclear to what extent serum FGF23 levels are affected in patients with DR. This study showed that serum FGF23 levels were 18 pg/ml or less in 18 infants with DR and was below 10 pg/ml in 72% of these. We previously described a maximum serum FGF23 level of 23.9 pg/ml in hypophosphatemic patients with vitamin D deficiency, Fanconi syndrome, and Cushing's syndrome whose ages ranged from 1 to 75 years [21]. Other researchers have reported that serum intact FGF23 levels were 23.4 pg/ml (mean) in adult females with vitamin D deficiency, a 36% reduction compared to those [36.7 pg/ml (mean)] in healthy control subjects [24]. Serum phosphate concentrations were not reduced in patients with vitamin D deficiency, while bone mineralization was not assessed. In our study, the mean serum FGF23 levels in 18 infants with DR was 8.4 pg/ml, a 71% reduction compared to those [28.9 pg/ml (mean)] in healthy control adults [25], although there could be a difference in FGF23 levels between healthy infants and adults. Thus, serum FGF23 levels in patients with vitamin D deficiency might vary depending on age, serum phosphate concentration, or defective bone mineralization. FGF23 levels less than 19 pg/ml might be useful to distinguish patients with rickets due to vitamin D deficiency from those with rickets due to FGF23 excess who might also be vitamin D deficient.

Serum FGF23 levels in patients with HR were 70.8 ± 11.5 pg/ml (mean ± SD) with a minimum value of 58 pg/ml. This is consistent with previous reports [25, 26] and also our previous study which suggested that FGF23 levels more than 30 pg/ml with hypophosphatemia indicate the presence of excessive FGF23-related diseases such as HR [21].

The nutritional and lifestyle survey of our patients showed that a majority with DR had been exclusively fed with breast milk before solid foods and that some patients had a restricted and/or unbalanced diet and limited sun exposure. Limited vitamin D intake and sun exposure are causes of DR without intrinsic diseases [13]. Supplementation with vitamin D for infants is recommended in many countries [27]. However, no recommendation for vitamin D supplementation is given in Japan. Considering patients with DR were mostly fed exclusively with breast milk, a recommendation concerning vitamin D

Downloaded by:
Osaka University

supplementation for infants is necessary in Japan to decrease the prevalence of DR.

Patients with DR exhibited an increase in serum PTH and $1,25(OH)_2D$ levels. Although $1,25(OH)_2D$ and PTH are thought to induce the expression of FGF23 in bone [17, 28], this is not the case in our study. The finding of the striking reduction of FGF23 levels in patients with DR indicates hypovitaminosis D and/or a chronic decrease in serum phosphate levels might have more influence on the decreased FGF23 expression, thereby overcoming any increase caused by 1,25(OH)2D and PTH. On the other hand, the patient with HR complicated by vitamin D deficiency displayed an increased FGF23 level, suggesting that the intrinsic genetic abnormality may have more of an impact on FGF23 expression than that caused by vitamin D deficiency. Further study is necessary to elucidate the mechanism(s) regulating FGF23 synthesis in osteocytes.

Serum FGF23 levels were increased after intervention using α-calcidol combined with lifestyle advice. The increases in FGF23 levels were accompanied by increases in serum phosphate concentrations, raising the possibility that increased serum phosphate could increase FGF23. Although FGF23 regulates serum phosphate by inhibiting renal tubular reabsorption, the effects of phosphate on FGF23 remain unclear [29]. However, it is known that $1,25(OH)_2D$ is an important systemic regulator of FGF23 that induces FGF23 expression. Thus, in our study, $1,25(OH)_2D$ derived from α-calcidol might directly increase FGF23. Another possible mechanism for the increased FGF23 is that lifestyle advice for adequate sun exposure and diet might improve hypovitaminosis D although 25(OH)D levels were not measured after intervention.

Our study has several limitations. First, the sample size is small. However, our results indicate that serum FGF23 levels are distinctly decreased in patients with DR compared to those with HR. Second, we did not have a control group composed of healthy infants, although it does not seem ethical to obtain blood samples from healthy infants. Third, genetic analysis was not performed in patients with HR. However, X-linked HR is the most common type of HR and other forms of HR are much less prevalent.

In summary, our study revealed that the measurement of serum FGF23 levels was highly useful for distinguishing infants with HR from those with DR, as serum FGF23 levels were exclusive between DR and HR. It is also suggested that serum FGF23 levels might be a good indication of biochemical response to the intervention in patients with DR.

Acknowledgements

This work was supported in part by Grants-in-Aid from the Ministry of Health, Labour, and Welfare of Japan (to K.O.).

References

1 Mughal MZ: Rickets. Curr Osteoporos Rep 2011;9:291–299.
2 Wharton B, Bishop N: Rickets. Lancet 2003; 362:1389–1400.
3 Absoud M, Cummins C, Lim MJ, Wassmer E, Shaw N: Prevalence and predictors of vitamin D insufficiency in children: a Great Britain population based study. PLoS One 2011; 6:e22179.
4 Carpenter TO, Herreros F, Zhang JH, Ellis BK, Simpson C, Torrealba-Fox E, Kim GJ, Savoye M, Held NA, Cole DE: Demographic, dietary, and biochemical determinants of vitamin D status in inner-city children. Am J Clin Nutr 2012;95:137–146.
5 Cesur Y, Dogan M, Ariyuca S, Basaranoglu M, Bektas MS, Peker E, Akbayram S, Caksen H: Evaluation of children with nutritional rickets. J Pediatr Endocrinol Metab 2011;24:35–43.
6 Akazawa Y, Shiohara M, Amano Y, Uchida N, Nakamura S, Minami I, Yasui K, Kurata K, Koike K: The clinical characteristics of vitamin D deficiency in childhood: a systematic literature review of Japanese patients. J Pediatr Endocrinol Metab 2010;23:675–684.
7 Matsuo K, Mukai T, Suzuki S, Fujieda K: Prevalence and risk factors of vitamin D deficiency rickets in Hokkaido, Japan. Pediatr Int 2009;51:559–562.
8 Yorifuji J, Yorifuji T, Tachibana K, Nagai S, Kawai M, Momoi T, Nagasaka H, Hatayama H, Nakahata T: Craniotabes in normal newborns: the earliest sign of subclinical vitamin D deficiency. J Clin Endocrinol Metab 2008; 93:1784–1788.
9 Kubota T, Kotani T, Miyoshi Y, Santo Y, Hirai H, Namba N, Shima M, Shimizu K, Nakajima S, Ozono K: A spectrum of clinical presentations in seven Japanese patients with vitamin D deficiency. Clin Pediatr Endocrinol 2006; 15:23–28.
10 Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM: Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96: 1911–1930.
11 Wimalawansa SJ: Vitamin D in the new millennium. Curr Osteoporos Rep 2012;10:4–15.
12 Saintonge S, Bang H, Gerber LM: Implications of a new definition of vitamin D deficiency in a multiracial US adolescent population: the National Health and Nutrition Examination Survey III. Pediatrics 2009;123: 797–803.
13 Wagner CL, Greer FR: Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008;122:1142–1152.
14 Holick MF: Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006;116: 2062–2072.
15 Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL: A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res 2011;26:1381–1388.
16 Carpenter TO: The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 2011;30:1–9.

Downloaded by:
Osaka University
133.1.67.196 - 3/10/2014 6:52:07 AM

17 Quarles LD: Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 2012;8:276–286.
18 Feng JQ, Clinkenbeard EL, Yuan B, White KE, Drezner MK: Osteocyte regulation of phosphate homeostasis and bone mineralization underlies the pathophysiology of the heritable disorders of rickets and osteomalacia. Bone 2013;54:213–221.
19 Fukumoto S: The role of bone in phosphate metabolism. Mol Cell Endocrinol 2009;310: 63–70.
20 Fujiwara M, Namba N, Ozono K, Arisaka O, Yokoya S; Committee on Drugs, Japanese Society for Pediatric Endocrinology: Treatment of hypophosphatemic rickets with phosphate and active vitamin D in Japan: a questionnaire-based survey Clin Pediatr Endocrinol 2013;22:9–14.
21 Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T: Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 2008; 42:1235–1239.
22 Stark H, Eisenstein B, Tieder M, Rachmel A, Alpert G: Direct measurement of TP/GFR: a simple and reliable parameter of renal phosphate handling. Nephron 1986;44:125–128.
23 Alon U, Hellerstein S: Assessment and interpretation of the tubular threshold for phosphate in infants and children. Pediatr Nephrol 1994;8:250–251.
24 Uzum AK, Salman S, Telci A, Boztepe H, Tanakol R, Alagol F, Ozbey NC: Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term. Eur J Endocrinol 2010; 163:825–831.
25 Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S: Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002;87:4957–4960.
26 Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H: Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348: 1656–1663.
27 Mimouni FB, Shamir R: Vitamin D requirements in the first year of life. Curr Opin Clin Nutr Metab Care 2009;12:287–292.
28 Penido MG, Alon US: Phosphate homeostasis and its role in bone health. Pediatr Nephrol 2012;27:2039–2048.
29 Martin A, David V, Quarles LD: Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012;92:131–155.

Downloaded by:
Osaka University

Bone 56 (2013) 375–382

Contents lists available at ScienceDirect

Bone

journal homepage: www.elsevier.com/locate/bone



Original Full Length Article

A human skeletal overgrowth mutation increases maximal velocity and blocks desensitization of guanylyl cyclase-B☆

Jerid W. Robinson [a,1], Deborah M. Dickey [b,1], Kohji Miura [c], Toshimi Michigami [d], Keiichi Ozono [c], Lincoln R. Potter [a,b,*]

[a] Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA
[b] Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA
[c] Department of Pediatrics, Osaka Graduate School of Medicine, Osaka, Japan
[d] Department of Bone and Mineral Research, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan

ARTICLE INFO

Article history:
Received 18 February 2013
Revised 12 June 2013
Accepted 24 June 2013
Available online 1 July 2013

Edited by: R. Baron

Keywords:
Natriuretic peptides
Guanylate cyclase
Bone growth
cGMP
Dwarfism
Achondroplasia

ABSTRACT

C-type natriuretic peptide (CNP) increases long bone growth by stimulating guanylyl cyclase (GC)-B/NPR-B/NPR2. Recently, a Val to Met missense mutation at position 883 in the catalytic domain of GC-B was identified in humans with increased blood cGMP levels that cause abnormally long bones. Here, we determined how this mutation activates GC-B. In the absence of CNP, cGMP levels in cells expressing V883M-GC-B were increased more than 20 fold compared to cells expressing wild-type (WT)-GC-B, and the addition of CNP only further increased cGMP levels 2-fold. In the absence of CNP, maximal enzymatic activity (Vmax) of V883M-GC-B was increased 15-fold compared to WT-GC-B but the affinity of the enzymes for substrate as revealed by the Michaelis constant (Km) was unaffected. Surprisingly, CNP decreased the Km of V883M-GC-B 10-fold in a concentration-dependent manner without increasing Vmax. Unlike the WT enzyme the Km reduction of V883M-GC-B did not require ATP. Unexpectedly, V883M-GC-B, but not WT-GC-B, failed to inactivate with time. Phosphorylation elevated but was not required for the activity increase associated with the mutation because the Val to Met substitution also activated a GC-B mutant lacking all known phosphorylation sites. We conclude that the V883M mutation increases maximal velocity in the absence of CNP, eliminates the requirement for ATP in the CNP-dependent Km reduction, and disrupts the normal inactivation process.

© 2013 Elsevier Inc. All rights reserved.

Introduction

C-type natriuretic peptide (CNP) stimulates long bone growth and inhibits meiotic resumption in oocytes by activating the enzyme variously known as guanylyl cyclase (GC)-B, natriuretic peptide receptor (NPR)-2 or NPR-B, which catalyzes the synthesis of the intracellular signaling molecule, cGMP [1–3]. GC-B is a homodimer containing an extracellular ligand-binding domain, a single membrane-spanning region, and an intracellular highly phosphorylated kinase homology domain, dimerization domain and C-terminal GC catalytic domain [4].

CNP binding increases GC-B activity by two mechanisms. It increases the maximal rate of cGMP production called maximal velocity (Vmax) and it also increases the affinity of the enzyme for GTP that is observed as a reduction in the Michaelis constant — the GTP concentration required to reach half the Vmax. Under non-physiologic conditions such as an enzyme assay where ATP is not present, the activity of GC-B is positive cooperative as demonstrated by a Hill coefficient of greater than 1. This means that GTP binds an allosteric site that increases the affinity of the catalytic site for GTP. However, under biological conditions where ATP concentrations are at or above 1 mM, the Hill coefficient of GC-B is 1 because the allosteric site is occupied by ATP not GTP. Recently, we demonstrated that ATP is required for the CNP-dependent reduction in the Km of GC-B [5,6]. Finally, in broken cell assays, ATP also increases GC-B activity by providing the phosphate that is added to the serine and threonine residues on the enzyme that is necessary for activation by CNP [7,8].

GC-B was identified in rat chondrocytes in 1994 [9], but the ability of natriuretic peptides to stimulate skeletal growth was first observed in transgenic mice overexpressing BNP in 1998 [10]. Subsequent bone culture studies indicated that CNP, not BNP, increased the proliferative and hypertrophic zones of the murine growth plate, which increases the length of long bones [10]. CNP also increases the earliest stage of endochondral bone development – the condensation of mesenchymal precursor cells – as well as stimulates glycosaminoglycan synthesis and extracellular matrix production [11,12]. Consistent with the requirement of CNP and GC-B in normal long bone growth in mammals, mice lacking either CNP or GC-B were dwarfs [13,14], and mice lacking the

Abbreviations: CNP, C-type natriuretic peptide; GC, guanylyl cyclase; NP, natriuretic peptide; WT, wild type.

☆ Disclosure statement: The authors have nothing to declare.

* Corresponding author at: University of Minnesota — Twin Cities, 6-155 Jackson Hall, 321 Church St. SE, Minneapolis, MN 55455, USA. Fax: +1 612 624 7282.
E-mail address: potter@umn.edu (L.R. Potter).
[1] Contributed equally to this manuscript and should be considered co-first authors.

8756-3282/$ – see front matter © 2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.bone.2013.06.024

natriuretic peptide clearance receptor (NPR-C) that degrades CNP exhibited skeletal hyperplasia [15,16]. In contrast, mice lacking BNP display no skeletal abnormalities [17]. Importantly, CNP and CNP analogs were recently shown to increase long bone growth in murine models of achondroplasia [18–20].

Homozygous inactivating mutations in both alleles of GC-B were identified in humans with acromesomelic dysplasia, type Maroteaux (AMDM) dwarfism [21–23], and heterozygous mutations in GC-B were associated with non-pathological reductions in human stature [24]. Conversely, mutations associated with CNP overexpression were identified in patients with skeletal overgrowth [25,26], and a genome-wide association study identified correlations between genetic mutations that regulate CNP or NPR-C expression and height in Northwestern European populations [27].

In 2012, Miura et al. identified a conserved valine to methionine missense mutation at position 883 in the catalytic domain of human GC-B (V883M-GC-B) in three generations of a Japanese family with skeletal overgrowth, fragile bones and elevated blood cGMP concentrations [28]. Importantly, how this mutation increases GC-B activity was not determined. Here, we show that this single residue substitution increases the maximal velocity of GC-B in the absence of CNP and that CNP reduces the Km of V883M-GC-B an order of magnitude without ATP or without increasing maximal velocity. Unexpectedly, the V883M substitution blocked the normal inactivation process.

Materials and methods

Reagents

^{125}I-cGMP radioimmunoassay kits and ^{32}P-α-GTP were from Perkin Elmer (Waltham, MA). CNP-22 was purchased from Sigma (St. Louis, MO). The plasmids encoding the N-terminally HA-tagged form of WT human GC-B (HA-WT-GC-B) [22] and HA-V883M-GC-B plasmids [28] have been described. The plasmids expressing rat GC-B-7A and GC-B-7E were also previously described [29,30]. The ATDC5 chondrocytes were from ATCC (www.atcc.org).

Cells and transfections

293 neocells were maintained and transiently transfected by the HEPES–calcium-phosphate precipitation method as previously reported [30].

Whole cell cGMP elevation assays

Cyclic GMP concentrations were measured by radioimmunoassay in ethanol extracts of transiently transfected 293 cells that were pre-incubated with 1 mM isobutylmethyl xanthine, a general phosphodiesterase inhibitor, for 10 min before being incubated with increasing concentrations of CNP as previously described [31].

Guanylyl cyclase assays

Crude membranes were prepared at 4 °C in phosphatase inhibitor buffer consisting of 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid — pH 7.4, 50 mM NaCl, 20% glycerol, 50 mM NaF, 1 mM EDTA, 0.5 μM microcystin and 1× Roche protease inhibitor cocktail. All assays were performed at 37 °C in a cocktail containing 25 mM HEPES pH 7.4, 50 mM NaCl, 0.1% BSA, 0.5 mM isobutylmethyl xanthine, 1 mM EDTA, 0.5 μM microcystin, 5 mM phosphocreatine, 0.1 μg/μl creatine kinase and 5 mM $MgCl_2$.

The single substrate concentration GC assays were performed using ^{32}P-GTP as substrate in the presence of 1 mM ATP and 1 mM GTP at 37 °C for 3 min as previously described [31]. For the desensitization assays, the reaction was performed using a pool of crude membranes. The reaction was initiated by the addition of pre-warmed cocktail. At the designated times, 0.1 ml aliquots were removed and added to ice-cold tubes containing 0.5 ml zinc acetate to stop the reaction. Alumina column chromatography purified the ^{32}P-cGMP, which was quantified by Cerenkov counting [32].

Substrate-velocity assays were performed for the indicated times with the indicated GTP concentrations. The resulting cGMP concentrations were determined by radioimmunoassay as described [33]. When included, free manganese concentrations in the assays were 2 mM. Because enzymatic activity was not completely linear with time, the kinetic parameters obtained under these conditions are considered "apparent".

Western blotting

293T cells were transfected with the indicated constructs, immunoprecipitated, fractionated by reducing SDS-PAGE and blotted to an Immobilon membrane for immune-detection as previously described [34]. The blot was blocked and probed with at 1/2500 dilution of rabbit serum 6328 followed by incubation with a 1/20,000 dilution of goat anti-rabbit IRDye 680 conjugated antibody and visualized on a LI-COR instrument as previously described [35].

Statistical analysis

Statistics and graphs were generated with Prism 5 software. Student's paired *t*-test determined significance where $p \leq 0.05$ was considered significant. The vertical bars within the symbols represent the SEM. Where not visible the bars are contained within the symbol. EC_{50} values were calculated based on the nonlinear curve fitting equation $Y = Top * X / (EC_{50} + X)$. Substrate–velocity curves were analyzed using an allosteric sigmoidal model to generate Hill coefficients.

Results

Cyclic GMP is elevated more than twenty-fold in cells expressing GC-B-V883M

HEK293 cells were transiently transfected with human isoforms of HA-WT-GC-B or HA-V883M-GC-B. Two days later, the cells were incubated in the presence of increasing concentrations of CNP for 3 min and intracellular cGMP concentrations were determined (Fig. 1A). Basal (no CNP) cGMP concentrations were elevated 21-fold in cells expressing HA-V883M-GC-B compared to cells expressing HA-WT-GC-B. Maximal concentrations of CNP increased cGMP concentrations 29-fold in HA-WT-GC-B expressing cells but only 2-fold in cells expressing HA-V883M-GC-B. The EC_{50} for CNP activation was not significantly different between the WT and mutant enzymes, consistent with the mutation not affecting the affinity of CNP for GC-B.

Plasmids expressing WT and GC-B-V883M were also transiently transfected into ATDC5 mouse chondrocytic cells that endogenously express GC-B. Since these cells express phosphodiesterases 1 and 5, we pretreated them with a general phosphodiesterase to emphasize cGMP synthesis by GC-B [36]. Overexpression of WT-GC-B slightly elevated cyclic GMP concentrations in the ATDC5 cells, but overexpression of the GC-B-V883M mutant resulted in cGMP levels that were more than four-fold higher than those observed in cells transfected with the WT enzyme (Fig. 1B). These data indicate that the increased basal activity associated with the V883M mutation occurs in a natural cellular environment for GC-B and is consistent with the increased plasma cGMP concentrations measured in patients expressing V883M-GC-B [28].

Basal enzymatic activity of V883M-GC-B is elevated but expression is reduced

GC activity was measured in crude membranes from 293 cells expressing green fluorescent protein (GFP) as a control, WT-GC-B,